R
ecent studies have shown a significant trend towards the use of surgical bioprosthetic valves in patients with aortic stenosis, mainly because of the avoidance of life-long anticoagulation therapy. 1 However, limited durability remains the main issue of bioprosthetic valves, with many patients experiencing bioprosthetic valve dysfunction requiring reintervention over time. 2, 3 According to current guidelines, redo surgical aortic valve replacement (SAVR) is the standard of care for treating bioprosthesis dysfunction. 4 However, patients with aortic bioprosthesis failure are commonly elderly, with multiple comorbidities leading to a high surgical risk. 5, 6 Indeed, some studies have shown that redo SAVR carries a higher risk of mortality and periprocedural complications compared with SAVR for native aortic valve stenosis. 7 More recently, transcatheter valve-in-valve (ViV) aortic valve replacement (TAVR) has emerged as a less invasive alternative to redo SAVR for inoperable or high-risk patients with degenerative bioprosthesis. 2 Several studies have shown good early and midterm (1 year) outcomes after ViV-TAVR, similar to those obtained in native aortic stenosis. 2, 8, 9 However, scarce data exist on long-term outcomes in ViV-TAVR recipients. In particular, the lack of late outcome data on valve hemodynamics is of special concern considering the higher rate of suboptimal immediate hemodynamic results, with high transvalvular gradients and a high incidence of severe prosthesis-patient mismatch (PPM) after ViV-TAVR procedures. 9, 10 The objective of our study was to determine the long-term (≥2 years) clinical and valve hemodynamic outcomes after ViV-TAVR.
METHODS
The data, analytic methods, and study materials will be available to other researchers for purposes of reproducing the results (the author for correspondence as well as the authors from each participating center should be contacted for the data). This was a multicenter study, including 116 consecutive patients, with degenerated surgical aortic bioprostheses who had ViV-TAVR between 2009 and 2015 in 9 centers. Eligibility for ViV-TAVR, valve type, and access route was determined at each center by the local heart team. Clinical, procedural, and echocardiographic data were prospectively collected in a database at each participating center. All events were classified according to the Valve Academic Research Consortium-2 (VARC-2) criteria. 11 Device success was also defined by VARC-2 criteria as absence of procedural mortality, correct positioning of a single prosthetic heart valve and intended performance of the prosthetic heart valve (no PPM and mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s and no moderate or severe prosthetic valve regurgitation). 11 Procedural success was defined as correct positioning of the prosthetic heart valve with the absence of major adverse cardiac and cerebrovascular events during the in-hospital period. Clinical and echocardiography follow-up were undertaken at discharge and 1-year postprocedure and yearly thereafter. Median follow-up of the study population was 3.0 years (range, 2-7 years), and no patient was lost to follow-up. All procedures and data collection were performed in accordance to the Ethics Committee of each participating center, and patients provided signed informed consent for the procedures and anonymized data collection.
Echocardiography
Transthoracic echocardiograhy was performed in each center by experienced cardiologists based on guideline recommendations. 12 The mechanism of surgical valve failure was classified as stenosis, regurgitation, or combined. The degree of stenosis and regurgitation was classified according to guidelines (Table I in the Data Supplement) , 13, 14 and patients with at least moderate stenosis and regurgitation were classified as having combined bioprosthetic failure. Elevated residual gradients were defined as mean transprosthetic gradient ≥20 mm Hg at discharge echocardiogram. 15 Severe postoperative PPM was defined as an indexed effective orifice area <0.65 cm 2 /m 2 . 16 Color Doppler examination in multiple windows was used to distinguish between intraprosthetic versus paraprosthetic valve regurgitation. Severity of prosthetic valve regurgitation was assessed using a multiparameter integrative approach. 12, 17 During the follow-up period, a total of 76 patients (81% of the population at risk) had at least 1 echocardiographic examination ≥2 years post-TAVR. Absolute change in mean gradient was calculated as the gradient at follow-up minus the gradient at baseline postoperative echocardiogram. To further evaluate valve performance and severity of valve deterioration over time, we followed the recent definition of bioprosthetic structural valve degeneration (SVD).
3 SVD was divided into 2 stages: (1) subclinical SVD and (2) 
WHAT THE STUDY ADDS
• This is the first study to provide data on long-term outcomes (up to 7 years) post-valve-in-valve TAVR, showing an overall stability of valve hemodynamics over time, with no significant increase in mean transvalvular gradients or aortic regurgitation.
• The incidence of clinically relevant structural valve degeneration was 3.0%, which appears to be similar to the results obtained in TAVR for native aortic valves (1.7%-3.4%).
• Severe prosthesis-patient mismatch and mean valve gradient at discharge appeared not to be related to long-term survival after valve-in-valve TAVR. Cox proportional hazard models were used to identify the factors associated with cumulative mortality. All analyses were performed using a hierarchical method to account for between center variability. Time-to-event curves using the Kaplan-Meier method were calculated. Changes in mean transaortic gradient and aortic valve area (AVA) measurements over time were evaluated with repeated measures ANOVA. A P value <0.05 was considered statistically significant. Data were analyzed with the SAS statistical software, version 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
The main baseline and procedural characteristics of the study population are summarized in Table 1 . Mean age was 76±11 years, most patients (64.7%) were male, and the mean Society of Thoracic Surgeons score was 8.0±5.1%. Stenosis was the main mechanism of bioprosthetic valve dysfunction (41.4%), followed by regurgitation (36.2%), and combined-stenosis and regurgitation-dysfunction (22.4%). About half of the patients received a balloon-expandable Edwards valve (Edwards Lifesciences, Irvine, CA) and half a CoreValve system (Medtronic, Minneapolis, MN), and most procedures (70.7%) were performed through transfemoral approach.
The main results at 30 days are summarized in Table 2 . The rates of procedural success and device success were 94.8% and 37.9%, respectively. During the procedure, 13 patients (11.2%) needed a second valve, and 1 case of coronary obstruction was reported in a patient with stentless surgical valve dysfunction (aortic regurgitation) treated with a 23 mm Sapien valve. In the subgroup of patients who needed a second valve, there was no difference between the surgical (P=0.815) or transcatheter (P=0.098) valve type. The 30-day rates of stroke and mortality were 1.7% and 6.9%, respectively. The main echocardiographic results after ViV-TAVR showed a mean residual gradient of 18.5±10.5 mm Hg, with up to 46 patients (39.7%) exhibiting a mean gradient ≥20 mm Hg. Severe PPM was diagnosed in 41 patients (35.3%), and the incidence of moderate or severe aortic regurgitation was 4.3%. The use of a balloon-expandable valve (odds ratio, 4.80; 95% CI, 1.18-19.51; P=0.029) and small transcatheter valve size -23 mm-(odds ratio, 5.40; 95% CI, 1.59-18.4; P=0.007) were associated with high (>20 mm Hg) residual gradient post-ViV-TAVR.
Late Clinical Outcomes
A total of 30 patients (25.9%) died at follow-up, 20 of them (17.2%) from cardiovascular causes. The KaplanMeier curves for the main clinical events up to 5-year follow-up are shown in Figure 1 . The univariable model for determining the factors associated with increased mortality are shown in Table 3 . By univariable analysis, the factors associated with increased mortality were older age (hazard ratio [ 
Valve Hemodynamics at Follow-Up
The main data about valve hemodynamics up to 5-year follow-up (including all available echocardiographic examinations at each time point) are shown in Figure 2 . Mean transvalvular gradients and AVA remained stable over time (P=0.94 and P=0.44 for changes in mean gradient and AVA, respectively). Valve hemodynamic data, including only those patients with complete sequential echocardiographic examinations up to 2-year follow-up (n=61) are shown in Of the 99 patients alive at hospital discharge with at least 1 echocardiography examination at follow-up, 18 patients (18.2%) were diagnosed of SVD, with 3 (3.0%) and 15 (15.1%) patients exhibiting clinically relevant and subclinical SVD, respectively, during the follow-up period. The main features of the 3 cases with clinically relevant SVD are shown in Table II in the Data Supplement. Two patients had received an Edwards valve, and 1 patient received a CoreValve system. Clinically relevant SVD was diagnosed at the echocardiography performed at 2-year follow-up in 2 cases and at 4-year follow-up in 1 patient. The mechanism of SVD was stenosis in all of cases (mean gradient at follow-up: 48.2±5.9 versus 17.4±4.6 mm Hg at baseline post-TAVR and valve area at follow-up: 0.4±0.3 versus 1.0±0.1 cm 2 at baseline post-TAVR), with no significant changes in aortic regurgitation. Two patients were managed medically, and 1 patient had redo TAVR, and all patients were alive at last follow-up. Among those patients with subclinical SVD, 7 (46.7%) cases occurred within the first year post-TAVR, whereas 8 (53.3%) cases were diagnosed ≥2 years post-TAVR. The main mechanism of subclinical SVD was stenosis in 13 patients and mixed (stenosis and regurgitation) in 2 patients (mean gradient at follow-up: 27.2±6.3 versus 14.6±6.6 mm Hg at baseline post-TAVR; P<0.001 and valve area at follow-up: 1.1±0.3 versus 1.4±0.5 cm 2 at baseline post-TAVR; P=0.09). There were no cases of isolated valve regurgitation as mechanism of SVD. The changes over time in mean gradient and AVA among those patients diagnosed of SVD are shown in Figure 4 . In 9 patients, at least 1 additional echocardiographic examination was available after the diagnosis of SVD. In these patients, the initial increased gradients remained stable over time (P=0.31), with no further significant increases in mean gradient up to 5-year follow-up.
The main baseline and procedural characteristics of those patients diagnosed with SVD compared with Values are mean±SD (N), (n) %. AR indicates aortic regurgitation; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; and TAVR, transcatheter aortic valve replacement. Table 4 . The demographic and periprocedural characteristics were similar in patients with and without SVD.
DISCUSSION
The present analysis is the first to date determining long-term clinical and echocardiographic outcomes in patients undergoing ViV-TAVR. The main findings showed that about one-fourth of patients had died after a median follow-up of 3 years. Valve hemodynamics remained overall stable over time (up to 5-year follow-up), but some degree of SVD was detected in 18.2% of patients (clinically relevant in only 3.0%).
Clinical Outcomes
The 30-day mortality rate in our study (6.9%) was slightly lower than that predicted by Society of Thoracic Surgeons score (8.0%) and similar to that reported after redo SAVR in a lower risk population. 18, 19 These results are also in accordance with previous ViV-TAVR studies. 2, 8 About periprocedural complications, the need for a second valve rate (≈11%) is similar to that reported in previous ViV-TAVR studies 2, 8 but higher than the incidence observed after TAVR in native valves. 20 Positioning challenges in those cases with aortic regurgitation as a predominant mechanism of valve failure (frequently associated with a low degree of valve calcification), the higher (more aortic) positioning of the valve to improve hemodynamics outcome, and the lack of fluoroscopic markers in some stentless valves have been proposed as potential mechanisms favoring this high rate of need for a second valve during ViV-TAVR procedures. 2 The use of newer generation valves with repositionability/ retrievability capabilities should help to decrease the rate of valve malpositioning embolization during these procedures. 21 However, and according to previous ViV-TAVR studies, the rate of pacemaker implantation (5%) appeared to be lower than that reported in TAVR for native aortic valves, 22 probably because of the potential protective effect of the surgical valve structure and a possible higher implantation of the transcatheter valve in ViV cases.
Data on late clinical outcomes showed that about one-fourth of the study population had died after a median follow-up of 3 years. This mortality rate seems to be slightly lower compared with previous studies in the TAVR field, including high-risk patients with native aortic stenosis. 23, 24 Although multiple confounding factors may have influenced such differences, the limitations of Society of Thoracic Surgeons score in the risk evaluation of TAVR candidates, 25 and the higher prevalence of baseline comorbidities in the native aortic stenosis versus ViV population with a similar surgical risk score may partially explain the improved late outcomes in our study patients. Also, the improved rates of significant paravalvular leaks in ViV-TAVR procedures, even with the use of first-generation transcatheter valves, may have also contributed to the better late survival rates.
Older age, lower LVEF, renal insufficiency, nontransfemoral approach, and balloon-expandable and smaller valves associated with increased mortality risk. PPM and a higher residual gradient were associated with poorer midterm outcomes in previous ViV-TAVR studies, 8, 10 but we have failed to demonstrate an association between these factors and long-term outcomes after ViV-TAVR. Our results are consistent with a recent publication involving ViV-TAVR patients, which did not demonstrate association of severe PPM or elevated residual gradient with VARC II-defined outcomes or 1-year survival, 26 suggesting that after VIV procedures, clinical characteristics and comorbidities may play a more important role in mid and longterm survival than hemodynamics data. According to our results, older age has already been shown to negatively influence late survival after both SAVR and TAVR for treating native aortic valve stenosis. 2, 27, 28 Also, our results showing an association between lower LVEF and nontransfemoral approach (particularly transapical) and increased mortality are similar to prior studies in the TAVR field. 29, 30 The smaller size of many of the last-generation transcatheter valve systems has translated into a major decrease Values are expressed as n (%). AR indicates aortic regurgitation; LVEF, left ventricular ejection fraction; and PPM, patient-prosthesis mismatch.
in the need for nontransfemoral approaches, 21 and this may be associated with improved outcomes after ViV-TAVR procedures. Future studies are needed to evaluate potential strategies for improving outcomes among patients with low LVEF. Finally, receiving a balloon-expandable valve was associated with a higher risk of death in our univariable model, but there were several significant differences between the balloonand self-expandable valve groups (lower LVEF, smaller valves, and more nontransfemoral approach in the balloon-expandable group) which could partially justify these differences.
Valve Hemodynamics and SVD After ViV-TAVR
The presence of higher residual transvalvular gradients has been reported after ViV-TAVR procedures compared with TAVR for treating native aortic stenosis. 2, 8, 10 This has been related to the smaller internal diameter because of the presence of the surgical bioprosthetic frame, along with the occurrence of moderate or severe PPM in a significant proportion of patients immediately after the initial SAVR intervention. 31, 32 Although the rate of severe PPM in our study (35.3%) is higher when compared with TAVR in native valve, 33, 34 it is similar or lower than that reported in previous ViV-TAVR studies (24.6%-58.4%). 8, 10, 26 Similar to previous ViV-TAVR studies, the mean transvalvular residual gradient observed in our study was 18.5 mm Hg, with up to 40% of patients exhibiting a mean residual gradient >20 mm Hg. This aspect has to be considered when deciding the treatment strategy (SAVR versus TAVR), particularly in those patients with small surgical bioprosthesis presenting with stenosis as the main mechanism of valve dysfunction. Also, promising preliminary results have been reported with newer techniques (eg, high-pressure balloon postdilatation, bioprosthetic valve leaflet fracture) for improving valve hemodynamics after ViV-TAVR procedures. 35, 36 Limited valve durability remains one of the major issues associated with bioprosthetic valves. RodriguezGabella et al 28 reported a 6.6% rate of clinically relevant SVD at 10-year follow-up in a large series of consecutive patients after SAVR with bioprosthetic valves. In TAVR studies for treating native aortic stenosis, rates of 1.7% to 3.4% of clinically relevant SVD up to 5-year follow-up have been reported. 3, 37 This first study providing data on valve durability up to 7 years post-ViV-TAVR, showed an overall stability of valve hemodynamics over time, with no significant increase in mean transvalvular gradients or aortic regurgitation. The incidence of clinically relevant SVD was 3.0%, which seems to be similar to the results obtained in TAVR for native aortic valves. However, some preliminary signs of valve deterioration leading to mild changes in valve hemodynamics (subclinical SVD) occurred in about 15% patients after a median follow-up of 3 years. This highlights the importance of continuous follow-up of these patients, with a frequency of echocardiographic examinations at followup that should probably need to increase with respect to current guideline recommendations. 38 No baseline or procedural characteristics were identified as factors increasing the risk of SVD post-ViV-TAVR. However, this may be related to the relatively low number of patients experiencing SVD, and studies with a larger number of patients will be needed to determine the predictors of SVD in these patients.
Limitations
This study was a retrospective analysis of prospectively collected data. There was no independent echocardiographic laboratory for analyzing the echo findings. Finally, transesophageal echocardiography or computed tomography examinations were not systematically performed in patients meeting the criteria for SVD. This precluded to completely rule out valve thrombosis as the mechanism of SVD in some cases. Finally, there was a limited number of patients and events in the study, and this precluded to perform a multivariable analysis to adjust for confounding factors about the factors associated with poorer clinical outcomes. Larger studies will be needed to confirm these results. 
Conclusions
This study showed acceptable long-term outcomes in high-risk patients undergoing ViV-TAVR. About 3 out of 4 patients survived after a median follow-up of 3 years, valve hemodynamics were stable over time, and there was a low rate of clinically relevant SVD. These data provide further support to ViV-TAVR as an alternative to redo SAVR for treating bioprosthetic aortic valve failure. However, a relatively high rate of subclinical SVD (≈15%) was observed, underscoring the importance of a systematic and close follow-up of these patients. Values are mean±SD (N), (n) %. AVA indicates aortic valve area; BMI, body mass index; BSA, body surface area; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; SVD, structural valve degeneration; STS, Society of Thoracic Surgeons; and TAVR, transcatheter aortic valve replacement.
